Monoclonal antibody used in the study of T cell diseases, and as a CAR therapy in T cell lymphoma/leukaemia. This antibody recognises human T cell receptor with the VÂ beta 3Â region
| Inventor | Institute |
|---|---|
| Mike Owen | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| Cat. #: | 152627 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cell biology;Immunology;Immuno-oncology;Immunophenotyping |
| Application: | FACS ; IHC ; IP ; Fn |
| Target: | V(beta)3 T cell receptor (TcR) |
| Reactivity: | Human |
| Clone: | JOVI.3 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | Monoclonal antibody used in the study of T cell diseases, and as a CAR therapy in T cell lymphoma/leukaemia. Background and Research Application The T cell receptor is heterodimer of alpha/beta or gamma/delta chains, expressed on all mature T cells. TCR's recognise antigen peptides bound to MHC molecules, providing the basis of antigen specific response by T cells. JOVI.3 can be used for studies of T cell mediated diseases, including autoimmunity and allergy. The antibody recognises any human T cell receptor that has the V beta 3 region, staining 50-75% of peripheral blood T cells and T cell lines. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG2a |
| Immunogen: | Thymus, spleen and mesenteric lymph nodes isolated from a mouse transgenic for human Vb3 TcR. |
| Immunogen Uniprot ID: | P09693 |
| Myeloma used: | P3/NS1/1-Ag4.1 |
| Target background: | Monoclonal antibody used in the study of T cell diseases, and as a CAR therapy in T cell lymphoma/leukaemia. Background and Research Application The T cell receptor is heterodimer of alpha/beta or gamma/delta chains, expressed on all mature T cells. TCR's recognise antigen peptides bound to MHC molecules, providing the basis of antigen specific response by T cells. JOVI.3 can be used for studies of T cell mediated diseases, including autoimmunity and allergy. The antibody recognises any human T cell receptor that has the v?3 region, staining 50-75% % of peripheral blood T cells and T cell lines. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Viguier et al. 2015. J Invest Dermatol. 135(2):418-24. PMID: 25207820. Peripheral and local human papillomavirus 16-specific CD8+ T-cell expansions characterize erosive oral lichen planus. San Jos et al. 1999. J Biol Chem. 274(47):33740-6. PMID: 10559266. Receptor engagement transiently diverts the T cell receptor heterodimer from a constitutive degradation pathway. Sahuquillo et al. 1998. J Exp Med. 187(8):1179-92. PMID: 9547330. T cell receptor (TCR) engagement in apoptosis-defective, but interleukin 2 (IL-2)-producing, T cells results in impaired ZAP70/CD3-zeta association. Viney et al. 1992. Hybridoma. 11(6):701-13. PMID: 1284120. Generation of monoclonal antibodies against a human T cell receptor beta chain expressed in transgenic mice. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151034 | Anti-HSVUL42 [13D11] |
Key Info
Anti-HSVUL42 [13D11]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.